99658-03-4

99658-03-4 structure

Name: α-Helical CRF (9-41) trifluoroacetate salt
Chemical Name: Corticotropin Releasing Factor Antagonist
CAS Number: 99658-03-4
Molecular Formula: C₁₆₆H₂₇₄N₄₆O₅₃S₂
Molecular Weight: 3826.36
Catalog: Signaling Pathways GPCR/G Protein CRFR
Create Date: 2018-12-04 16:25:39
Modify Date: 2024-01-02 00:46:29
α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo[1][2].

Name	Corticotropin Releasing Factor Antagonist
Synonyms	MFCD00081543

Description	α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo[1][2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> CRFR Research Areas >> Inflammation/Immunology
In Vivo	α-Helical Corticotropin Releasing Factor (9-41) (10 μg; the third or lateral ventricle of the brain injection; once) significantly decreases plasma GH values[1]. α-Helical Corticotropin Releasing Factor (9-41) (100 ng/kg; i.c.v. once) affects rhlL-1/β-induced enhancement of the splenic sympathetic activity[2]. Animal Model: Adult Sprague-Dawley rats[1] Dosage: 10 μg Administration: The third or lateral ventricle of the brain injection; 10 μg once Result: Abolished the 10 min electroshocks-produced the decreasing of plasma GH levels by injected into the third or lateral ventricle of the brain 45 min before exposure to stress. Animal Model: Adult Sprague-Dawley rats with immunity of endogenous somatostatin (SS)[1] Dosage: 10 μg Administration: Lateral ventricle brain injection; 10 μg once Result: Showed no effect on plasma GH values in rats whose endogenous SS had been immunoneutralized, but did interfere with the stimulatory effect of GH-releasing factor (GRF). Animal Model: Male Wistar rats with rhlL-1/β injection[2] Dosage: 100 ng/kg Administration: Intracerebroventricularly injection; 100 ng/kg once Result: Completely blocked the rhlL-1/β-induced enhancement of the splenic sympathetic activity, but failed to alter the enhancement of nociceptive behaviors caused by rhlL-1/β.
References	[1]. Rivier C, Vale W. Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat. Endocrinology. 1985 Dec;117(6):2478-82. [2]. Takakazu Oka, et al. Intracerebroventricular injection of interleukin-1/β induces hyperalgesia in rats. Brain Research, 624 (1993) 61-68.

Density	1.5±0.1 g/cm3
Boiling Point	717.1±60.0 °C at 760 mmHg
Molecular Formula	C₁₆₆H₂₇₄N₄₆O₅₃S₂
Molecular Weight	3826.36
Flash Point	387.5±32.9 °C
Exact Mass	540.075745
LogP	3.33
Vapour Pressure	0.0±2.4 mmHg at 25°C
Index of Refraction	1.602

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
RIDADR	NONH for all modes of transport

99658-03-4	158535-55-8
90880-23-2	34273-12-6
134009-09-9	154040-19-4
332867-16-0	1926163-14-5
581-05-5	799241-26-2
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1658464-58-4	1018584-77-4
1375289-11-4	1595810-73-3